Fosnetupitant Chloride Hydrochloride
A specific salt form of fosnetupitant, an intravenous prodrug of netupitant used in combination regimens to prevent nausea and vomiting associated with highly emetogenic chemotherapy. This formulation is converted to active netupitant in the body, which then blocks neurokinin-1 receptors involved in the vomiting reflex. The chloride hydrochloride salt improves stability and solubility for intravenous use.
分子量
761.5000 g/mol
TPSA
103.00 Ų
作用機序
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
2D構造
Cite this structure
Embed this structure
SMILES
Cc1ccccc1-c1cc(N2CC[N+](C)(COP(=O)(O)O)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1.Cl.[Cl-]
InChI
InChI=1S/C31H35F6N4O5P.2ClH/c1-20-8-6-7-9-24(20)25-17-27(40-10-12-41(5,13-11-40)19-46-47(43,44)45)38-18-26(25)39(4)28(42)29(2,3)21-14-22(30(32,33)34)16-23(15-21)31(35,36)37;;/h6-9,14-18H,10-13,19H2,1-5H3,(H-,43,44,45);2*1H
Molecular Formula
C31H37Cl2F6N4O5P
HBD / HBA
3 / 14
回転可能結合数
8
重原子数
49
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
A specific salt form of fosnetupitant, an intravenous prodrug of netupitant used in combination regimens to prevent nausea and vomiting associated with highly emetogenic chemotherapy. This formulation is converted to active netupitant in the body, which then blocks neurokinin-1 receptors involved in the vomiting reflex. The chloride hydrochloride salt improves stability and solubility for intravenous use.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Fosnetupitant Chloride Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989919. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 86764535. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="fosnetupitant-chloride-hydrochloride"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/fosnetupitant-chloride-hydrochloride/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/fosnetupitant-chloride-hydrochloride/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/fosnetupitant-chloride-hydrochloride/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="fosnetupitant-chloride-hydrochloride"></drugfyi-drug>